ALPHA-FETOPROTEIN GLYCOSYLATION IS ABNORMAL IN SOME HEPATOCELLULAR CARCINOMAS, INCLUDING WHITE PATIENTS WITH A NORMAL ALPHA-FETOPROTEIN CONCENTRATION

被引:15
作者
AJDUKIEWICZ, AB
KELLEHER, PC
KRAWITT, EL
WALTERS, CJP
MASON, PB
KOFF, RS
BELANGER, L
机构
[1] UNIV VERMONT,COLL MED,DEPT MED,BURLINGTON,VT 05405
[2] MRC LABS,BANJUL,SENEGAMBIA
[3] UNIV VERMONT,COLL MED,DEPT PEDIAT,BURLINGTON,VT 05405
[4] METROWEST MED CTR,FRAMINGHAM,MA 01701
[5] UNIV LAVAL,CTR RECH CANCEROL,QUEBEC CITY G1R 2S6,PQ,CANADA
关键词
ALPHA-FETOPROTEIN; GLYCOSYLATION; TYROSINEMIA; CHRONIC HEPATITIS; HEPATOCELLULAR CARCINOMA;
D O I
10.1016/0304-3835(93)90042-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lectin-affinity analyses with Lens culinaris agglutinin (LCA) and other lectins have demonstrated that the glycosylation of alpha-fetoprotein (AFP) secreted by hepatocellular carcinomas (HCC) is frequently altered when the serum AFP concentration is increased. To determine if AFP LCA-binding properties are altered in patients with HCC whose serum AFP concentration is normal, the percentage of LCA-binding AFP in serum from white newborns, white normal adults, white patients with chronic hepatitis and hereditary tyrosinemia and white and black patients with HCC were determined. The serum LCA-binding AFP fraction was low in newborns (1-4%) and normal adults (1-8%). There was a significant increase in LCA-binding AFP in patients with chronic hepatitis (10-24%) and hereditary tyrosinemia (5-35%). The AFP LCA-binding fraction was clearly abnormal (greater than 40%) in three of the white patients with an HCC and a normal serum AFP concentration, and the range of values (10-63%) in these HCC patients was similar to that seen in both white and black patients with HCC accompanied by increased AFP concentrations.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 37 条
[1]  
Abelev G I, 1971, Adv Cancer Res, V14, P295, DOI 10.1016/S0065-230X(08)60523-0
[2]   LIVER ASPIRATION IN THE DIAGNOSIS OF HEPATOCELLULAR-CARCINOMA IN THE GAMBIA [J].
AJDUKIEWICZ, A ;
CROWDEN, A ;
HUDSON, E ;
PYNE, C .
JOURNAL OF CLINICAL PATHOLOGY, 1985, 38 (02) :185-192
[3]  
ALPERT E, 1976, HEPATOCELLULAR CARCI, P353
[4]  
ANTHONY PP, 1976, LIVER CELL CANCER, P93
[5]  
AOYAGI Y, 1988, CANCER-AM CANCER SOC, V61, P769, DOI 10.1002/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO
[6]  
2-M
[7]  
AOYAGI Y, 1985, LANCET, V2, P1353
[8]  
AOYAGI Y, 1984, JPN J CANCER RES, V75, P809
[9]  
BARAK M, 1989, ONCOLOGY, V46, P375
[10]  
BEASLEY RP, 1981, LANCET, V2, P1129